Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0345904 (liver cancer)
 15,188 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In order to study the expression of Lewis antigens and the subtypes of alpha1,3 fucosyltransferase(alpha1,3FucT) in human primary liver cancer, and their relations with the cancer cell embolus formation, as well as the expression of nm23-H1, a metastatic suppressor gene, Lewis antigens were detected with immunohistochemical method, and the mRNA of alpha1,3 FucTs and nm23-H1 were determined with Northern blot. Results showed that the positive rates of the expression of four Lewis antigens, sialyl Lewis X(Sle(x)), Lewis X(Le(x)), sialyl dimeric Lewis X(SDLe(x)) and sialyl Lewis A(Sle(a)), in human primary liver cancer were about 80%. The expression of Sle(x) was rather higher, Le(x) and Sle(a) were lower, but the expression of SDLe(x) was only in trace amount. The four Lewis antigens were not expressed in the liver regions adjacent to the cancer tissues. The transcriptional level of alpha1,3 FucT-III/VI mRNA in cancer tissues was higher than that in the adjacent regions, especially in the cancer tissues of patients with portal vein cancer cell embolus(CCE). However, the expression of alpha1,3 FucT-III/VI mRNA was not different in the adjacent regions in spite of the presence or absence of CCE in the patients. In contrast, the expression of alpha1,3 FucT-VII was rather lower and identical to each other both in cancer tissues and adjacent regions. In addition, it was found that the expression of nm23-H1, a metastasis suppressor gene, was markedly lower in the cancer tissues of patients with CCE than that in the non-CCE patients and the adjacent regions. Furthermore, the expression of nm23-H1 was negatively related to the expression of alpha1,3 FucT-III/VI. These results indicated that the expression of alpha1,3 FucT-III/VI and its product Sle(x) were correlated with CCE (metastatic potential), and the down-regulation of alpha1,3 FucT-III/VI and Sle(x) may be one of the mechanisms of nm23-H1 to inhibit liver cancer metastasis.
 ...
PMID:Lewis Antigens, alpha1,3 Fucosyltransferses and the Metastatic Potential of Human Primary Liver Cancer. 1209 86

The expressions of three X series Lewis antigens, including Lewis X (Le(x)), sialyl Lewis X (SLe(x)) and sialyl dimeric Lewis X (SDLe(x)) were studied with immuno-histochemical methods in human non-small cell pulmonary cancer (NSCPC) and primary liver cancer (PLC) with different pathological conditions. The Lewis antigens are mainly expressed on the cell surfaces, medially or slightly in the cytoplasm, but not in the cell nuclei of the cancer tissues. The regions adjacent to the cancer tissues do not express any Lewis antigens. The positive rates of these antigens in NSCPC were within the range of 75% to approximately 86%. There was no apparent difference in positive rates between the cases with different differentiation and the presence or absence of metastasis in peripheral lymph nodes, nor among the three antigens, except that the positive rate of SDLe(x) was lower (about 56%) in the cases with well/medium differentiation and without metastasis. However, the expression-intensities (SI indexes) of all three antigens were significantly higher in the samples of poor differentiation and with metastasis as compared to those with well/medium differentiation and without metastasis. The two sialyl Lewis antigens increased more significantly than non-sialylated Le(x). The expressions of these antigens were also observed in the peripheral lymph nodes with metastasis, but not in those without metastasis. The positive rates of Le(x), SLe(x) and SDLe(x) in human primary liver cancer were 83.3%, 88.9% and 77.8%, respectively. In the cases with cancer cell thrombosis (CCT) in portal vein (an index of metastasis), the expressions of all these three antigens were stronger than those in the cases without CCT. SLe(x) was the most abundant and most highly increased Lewis antigen on the surface of NSCPC and PLC, especially in the cases with poor differentiation and metastasis. In the study of the enzymatic basis of the increased Lewis antigens in PLC by using Northern blot, it was found that the level of alpha1,3 FucT-III/VI mRNA in PLC tissues was much higher than that in the adjacent regions, and more significantly higher in the cancer tissues from patients with CCT in portal vein. In contrast, the expression of alpha1,3 FucT-VII was rather low in cancer tissues and not different from the adjacent regions in spite of the presence or absence of CCT. These results reveal that the SLe(x) in PLC is mainly synthesized by alpha1,3 FucT-III/VI (especially VI) and is the most important Lewis antigen involved in the metastasis of PLC.
 ...
PMID:Expressions of Lewis antigens in human non-small cell pulmonary cancer and primary liver cancer with different pathological conditions. 1458 3